Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-STAGE, PHASE 2, DOUBLE-MASKED, RANDOMIZED, VEHICLE CONTROLLED, DOSE RESPONSE TRIAL OF PF-04217329 AND THE MARKETED FORMULATION OF LATANOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

NCT00572455 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00572455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00572455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-STAGE, PHASE 2, DOUBLE-MASKED, RANDOMIZED, VEHICLE CONTROLLED, DOSE RESPONSE TRIAL OF PF-04217329 AND THE MARKETED FORMULATION OF LATANOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 11, 2007
Completion date
June 26, 2009
Enrollment
318 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, primary open-angle glaucoma